US5032403A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Multilayer plaster
Assignee: Novartis Corp
•
Filing: 1989-07-28
•
Granted: 1991-07-16
•
Expires: 2009-07-28
Abstract
Abstract The invention relates to a transdermal therapeutic system in the form of a multilayer plaster for the administration of active substances which are able to permeate, in the form of a matrix system containing at least three layers: (a) a covering layer which is impermeable for the constituents of the reservoir b); (b) a reservoir layer which is able to deliver active substance and which consists of optionally crosslinked block copolymer based on styrene, alkadienes and optionally alkenes mixed with adhesive polymers and is optionally provided with an additional adhesive membrane layer and contains at least one active substance capable of skin permeation, at least one agent promoting the skin permeability of active substances and optionally further pharmaceutical auxiliaries, and (c) a protective film which can be pulled off the reservoir layer.
Inventors
- 👤 Joel Sinnreich
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 21:34
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7038; A61K9/7046; A61K9/7053; A61K47/00; A61K47/06; A61K47/22
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
117 words
A transdermal therapeutic system in the form of a multilayer plaster with the following constituents: (a) a covering layer which is impermeable to the constituents of the reservoir layer (b); (b) a reservoir layer which is able to deliver active substance and which consists of optionally crosslinked block copolymer based on styrene, alkadienes and optionally alkenes mixed with adhesive polymers and is optionally provided with an additional adhesive membrane layer and contains at least one pharmaceutically active agent capable of skin permeation, a combination of 70% 1,8-cineole and N-methyl-2-pyrrolidone as agent promoting the skin-permeability of the pharmaceutically active agent and optionally further pharmaceutical auxiliaries, and (c) a protective film which can be pulled off the reservoir layer.
Claim 2
Dependent Claim
117 words
A transdermal therapeutic system in the form of a multilayer plaster with the following constituents: (a) a covering layer which is impermeable to the constituents of the reservoir layer (b); (b) a reservoir layer which is able to deliver active substance and which consists of optionally crosslinked block copolymer based on styrene, alkadienes and optionally alkenes mixed with adhesive polymers and is optionally provided with an additional adhesive membrane layer and contains at least one pharmaceutically active agent capable of skin permeation, a combination of 70% 1,8-cineole and N-methyl-2-pyrrolidone as agent promoting the skin-permeability of the pharmaceutically active agent and optionally further pharmaceutical auxiliaries, and (c) a protective film which can be pulled off the reservoir layer.
Claim 3
Dependent Claim
33 words
Transdermal therapeutic system according to claim 1, characterized in that the reservoir layer (b) contains a combination of eucalyptol with a content of at least 70% 1,8-cineole and N-methyl-2-pyrrolidone as additional skin-penetrating agent.
Claim 4
Dependent Claim
31 words
Transdermal therapeutic system according to claim 1, characterized in that the reservoir layer (b) contains a combination of chemically pure 1,8-cineole (purity greater than 99%) and N-methyl-2-pyrrolidone as additional skin-penetrating agent.
Claim 5
Dependent Claim
36 words
Transdermal therapeutic system according to claim 1, characterized in that the combination of 1,8-cineole and N-methyl-2-pyrrolidone contains about 5-9.5 parts by weight of 1,8-cineole and, correspondingly, about 5-0.5 parts by weight (based on 10) of N-methyl-2-pyrrolidone.
Claim 6
Dependent Claim
31 words
Transdermal therapeutic system according to claim 4, characterized in that the combination of 1,8-cineole and N-methyl-2-pyrrolidone contains about 9 parts by weight of 1,8-cineole and 1 part by weight of N-methyl-2-pyrrolidone.
Claim 7
Dependent Claim
36 words
Transdermal therapeutic system according to claim 1, characterized in that the reservoir layer (b) contains nitroglycerine, scopolamine, formoterol, 17β-oestradiol or progesterone or combinations of 17β-oestradiol with norethisterone 17-acetate as active substances which are able to permeate.
Claim 8
Dependent Claim
52 words
Transdermal therapeutic system according to claim 1, characterized in that the reservoir layer (b) consists of ethylene/butadiene/styrene block polymers or butadiene/styrene block copolymers, which are wholly or partially crosslinked by exposure to high-energy radiation and which are mixed with polyisobutylene with an average molecular weight of 1.0×10 3 to 5×10 4 .
Claim 9
Dependent Claim
109 words
Transdermal therapeutic system according to claim 1 with the following constituents: (a) a covering which is impermeable for the constituents of the reservoir layer (b), (b) a reservoir layer which is able to deliver active substance and which consists of optionally crosslinked butadiene/styrene block copolymers or ethylene/butadiene/styrene block polymers mixed with polyisobutylene with a molecular weight range of about 1.0×10 3 to 5.0×10 4 and contains at least one active substance which is able to permeate through the skin, at least one agent promoting the skin permeability of active substances and optionally further pharmaceutical auxiliaries and, (c) a protective film which can be pulled off the reservoir layer (b).
Claim 10
Dependent Claim
90 words
Process for the production of a transdermal therapeutic system according to claim 1, characterized in that applied to the protective layer (c) which can be pulled off are the reservoir layer (b) with its constituents and, thereto, the covering layer (a), or the procedure is reversed and applied to the covering layer (a) are the reservoir layer (b) and, thereto, the protective film (c), and after one of the two process variants has been carried out, the layers are bonded together and the product is brought to the desired shape.
References Cited (Backward Citations)
US4440770A
Cited
US4560553A
Cited
US4623346A
Cited
US4627852A
Cited
US4699792A
Cited
US4668232A
Cited
US4776850A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-07-15 | 1995-01-14 | 1995-07-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-07-15 | 1999-01-14 | 1999-07-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-07-15 | 2003-01-14 | 2003-07-16 | $7700.00 | Window Closed / Lapsed |